Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients

Deborah L. Regidor, Csaba Kovesdy, Rajnish Mehrotra, Mehdi Rambod, Jennie Jing, Charles J. McAllister, David Van Wyck, Joel D. Kopple, Kamyar Kalantar-Zadeh

Research output: Contribution to journalArticle

153 Citations (Scopus)

Abstract

Several observational studies have demonstrated that serum levels of minerals and parathyroid hormone (PTH) have U- or J-shaped associations with mortality in maintenance hemodialysis patients, but the relationship between serum alkaline phosphatase (AlkPhos) and risk for all-cause or cardiovascular death is unknown. In this study, a 3-yr cohort of 73,960 hemodialysis patients in DaVita outpatient dialysis were studied, and the hazard ratios for all-cause and cardiovascular death were higher across 20-U/L increments of AlkPhos, including within the various strata of intact PTH and serum aspartate aminotransferase. In the fully adjusted model, which accounted for demographics, comorbidity, surrogates of malnutrition and inflammation, minerals, PTH, and aspartate aminotransferase, AlkPhos ≥120 U/L was associated with a hazard ratio for death of 1.25 (95% confidence interval 1.21 to 1.29; P < 0.001). This association remained among diverse subgroups of hemodialysis patients, including those positive for hepatitis C antibody. A rise in AlkPhos by 10 U/L during the first 6 mo was incrementally associated with increased risk for death during the subsequent 2.5 yr. In summary, high levels of serum AlkPhos, especially >120 U/L, are associated with mortality among hemodialysis patients. Prospective controlled trials will be necessary to test whether serum AlkPhos measurements could be used to improve the management of renal osteodystrophy.

Original languageEnglish (US)
Pages (from-to)2193-2203
Number of pages11
JournalJournal of the American Society of Nephrology
Volume19
Issue number11
DOIs
StatePublished - Nov 1 2008

Fingerprint

Alkaline Phosphatase
Renal Dialysis
Parathyroid Hormone
Maintenance
Mortality
Aspartate Aminotransferases
Serum
Minerals
Chronic Kidney Disease-Mineral and Bone Disorder
Malnutrition
Observational Studies
Comorbidity
Dialysis
Cause of Death
Outpatients
Demography
Confidence Intervals
Inflammation

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Regidor, D. L., Kovesdy, C., Mehrotra, R., Rambod, M., Jing, J., McAllister, C. J., ... Kalantar-Zadeh, K. (2008). Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. Journal of the American Society of Nephrology, 19(11), 2193-2203. https://doi.org/10.1681/ASN.2008010014

Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. / Regidor, Deborah L.; Kovesdy, Csaba; Mehrotra, Rajnish; Rambod, Mehdi; Jing, Jennie; McAllister, Charles J.; Van Wyck, David; Kopple, Joel D.; Kalantar-Zadeh, Kamyar.

In: Journal of the American Society of Nephrology, Vol. 19, No. 11, 01.11.2008, p. 2193-2203.

Research output: Contribution to journalArticle

Regidor, DL, Kovesdy, C, Mehrotra, R, Rambod, M, Jing, J, McAllister, CJ, Van Wyck, D, Kopple, JD & Kalantar-Zadeh, K 2008, 'Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients', Journal of the American Society of Nephrology, vol. 19, no. 11, pp. 2193-2203. https://doi.org/10.1681/ASN.2008010014
Regidor, Deborah L. ; Kovesdy, Csaba ; Mehrotra, Rajnish ; Rambod, Mehdi ; Jing, Jennie ; McAllister, Charles J. ; Van Wyck, David ; Kopple, Joel D. ; Kalantar-Zadeh, Kamyar. / Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. In: Journal of the American Society of Nephrology. 2008 ; Vol. 19, No. 11. pp. 2193-2203.
@article{8bf8107043974649bf7c6cc3a2940008,
title = "Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients",
abstract = "Several observational studies have demonstrated that serum levels of minerals and parathyroid hormone (PTH) have U- or J-shaped associations with mortality in maintenance hemodialysis patients, but the relationship between serum alkaline phosphatase (AlkPhos) and risk for all-cause or cardiovascular death is unknown. In this study, a 3-yr cohort of 73,960 hemodialysis patients in DaVita outpatient dialysis were studied, and the hazard ratios for all-cause and cardiovascular death were higher across 20-U/L increments of AlkPhos, including within the various strata of intact PTH and serum aspartate aminotransferase. In the fully adjusted model, which accounted for demographics, comorbidity, surrogates of malnutrition and inflammation, minerals, PTH, and aspartate aminotransferase, AlkPhos ≥120 U/L was associated with a hazard ratio for death of 1.25 (95{\%} confidence interval 1.21 to 1.29; P < 0.001). This association remained among diverse subgroups of hemodialysis patients, including those positive for hepatitis C antibody. A rise in AlkPhos by 10 U/L during the first 6 mo was incrementally associated with increased risk for death during the subsequent 2.5 yr. In summary, high levels of serum AlkPhos, especially >120 U/L, are associated with mortality among hemodialysis patients. Prospective controlled trials will be necessary to test whether serum AlkPhos measurements could be used to improve the management of renal osteodystrophy.",
author = "Regidor, {Deborah L.} and Csaba Kovesdy and Rajnish Mehrotra and Mehdi Rambod and Jennie Jing and McAllister, {Charles J.} and {Van Wyck}, David and Kopple, {Joel D.} and Kamyar Kalantar-Zadeh",
year = "2008",
month = "11",
day = "1",
doi = "10.1681/ASN.2008010014",
language = "English (US)",
volume = "19",
pages = "2193--2203",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "11",

}

TY - JOUR

T1 - Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients

AU - Regidor, Deborah L.

AU - Kovesdy, Csaba

AU - Mehrotra, Rajnish

AU - Rambod, Mehdi

AU - Jing, Jennie

AU - McAllister, Charles J.

AU - Van Wyck, David

AU - Kopple, Joel D.

AU - Kalantar-Zadeh, Kamyar

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Several observational studies have demonstrated that serum levels of minerals and parathyroid hormone (PTH) have U- or J-shaped associations with mortality in maintenance hemodialysis patients, but the relationship between serum alkaline phosphatase (AlkPhos) and risk for all-cause or cardiovascular death is unknown. In this study, a 3-yr cohort of 73,960 hemodialysis patients in DaVita outpatient dialysis were studied, and the hazard ratios for all-cause and cardiovascular death were higher across 20-U/L increments of AlkPhos, including within the various strata of intact PTH and serum aspartate aminotransferase. In the fully adjusted model, which accounted for demographics, comorbidity, surrogates of malnutrition and inflammation, minerals, PTH, and aspartate aminotransferase, AlkPhos ≥120 U/L was associated with a hazard ratio for death of 1.25 (95% confidence interval 1.21 to 1.29; P < 0.001). This association remained among diverse subgroups of hemodialysis patients, including those positive for hepatitis C antibody. A rise in AlkPhos by 10 U/L during the first 6 mo was incrementally associated with increased risk for death during the subsequent 2.5 yr. In summary, high levels of serum AlkPhos, especially >120 U/L, are associated with mortality among hemodialysis patients. Prospective controlled trials will be necessary to test whether serum AlkPhos measurements could be used to improve the management of renal osteodystrophy.

AB - Several observational studies have demonstrated that serum levels of minerals and parathyroid hormone (PTH) have U- or J-shaped associations with mortality in maintenance hemodialysis patients, but the relationship between serum alkaline phosphatase (AlkPhos) and risk for all-cause or cardiovascular death is unknown. In this study, a 3-yr cohort of 73,960 hemodialysis patients in DaVita outpatient dialysis were studied, and the hazard ratios for all-cause and cardiovascular death were higher across 20-U/L increments of AlkPhos, including within the various strata of intact PTH and serum aspartate aminotransferase. In the fully adjusted model, which accounted for demographics, comorbidity, surrogates of malnutrition and inflammation, minerals, PTH, and aspartate aminotransferase, AlkPhos ≥120 U/L was associated with a hazard ratio for death of 1.25 (95% confidence interval 1.21 to 1.29; P < 0.001). This association remained among diverse subgroups of hemodialysis patients, including those positive for hepatitis C antibody. A rise in AlkPhos by 10 U/L during the first 6 mo was incrementally associated with increased risk for death during the subsequent 2.5 yr. In summary, high levels of serum AlkPhos, especially >120 U/L, are associated with mortality among hemodialysis patients. Prospective controlled trials will be necessary to test whether serum AlkPhos measurements could be used to improve the management of renal osteodystrophy.

UR - http://www.scopus.com/inward/record.url?scp=55749092278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55749092278&partnerID=8YFLogxK

U2 - 10.1681/ASN.2008010014

DO - 10.1681/ASN.2008010014

M3 - Article

VL - 19

SP - 2193

EP - 2203

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 11

ER -